Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An In Silico Approach by Andrés Galindo Céspedes, Mércia Patrícia Ferreira Conceição, aniel Rodrigues de Bastos, Gabriela Ávila de Grazia, Jean Michel Rocha Sampaio Leite, Renan Gomes do Nascimento, Matthew Thomas Ferreira, Rossana Mendoza Lopez

“…Added together, the platforms included modules for correlation, expression, prognosis, drug interactions, and construction of gene networks.Results:Kaplan–Meier curves revealed that reduced levels of CYSLTR1 corresponded to an unfavorable outcome for overall survival (p<0.005) as well as relapse-free survival (p<0.001) in the basal subtype. …”
Get full text

New Hybrids of 4-Amino-2,3-polymethylene-quinoline and <i>p</i>-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Al... by Galina F. Makhaeva, Nadezhda V. Kovaleva, Natalia P. Boltneva, Sofya V. Lushchekina, Tatiana Yu. Astakhova, Elena V. Rudakova, Alexey N. Proshin, Igor V. Serkov, Eugene V. Radchenko, Vladimir A. Palyulin, Sergey O. Bachurin, Rudy J. Richardson

“…The compounds possessed low activity against carboxylesterase, indicating a likely absence of unwanted drug-drug interactions in clinical use. Kinetics studies were consistent with mixed-type reversible inhibition of both cholinesterases. …”
Get full text

Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing by Dominic Rauschning, Ira Ehren, Eva Heger, Elena Knops, Gerd Fätkenheuer, Isabelle Suárez, Clara Lehmann

“…Resistance to multiple antiretroviral drugs among people living with HIV (PLWH) can result in a high pill burden, causing toxicity and drug interactions. Thus, the goal is to simplify treatment regimens while maintaining effectiveness. …”
Get full text

Therapeutic Drug Monitoring and Pharmacogenetic Testing as Guides to Psychotropic Drug Dose Adjustment: An Observational Study by Elodie Cuvelier, Houda Khazri, Cloé Lecluse, Benjamin Hennart, Ali Amad, Jean Roche, Michel Tod, Guillaume Vaiva, Olivier Cottencin, Pascal Odou, Delphine Allorge, Bertrand Décaudin, Nicolas Simon

“…The objective of the present single-center observational study was to describe the changes in psychotropic drug management prompted by therapeutic drug monitoring and pharmacogenetic testing, and to compare the effective drug concentration based on metabolic status with the dose predicted using an in silico decision tool for drug–drug interactions. The study was conducted in psychiatry wards at Lille University Hospital (Lille, France) between 2016 and 2020. …”
Get full text

International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy by Jean-Baptiste Beuscart, Wilma Knol, Shane Cullinan, Claudio Schneider, Olivia Dalleur, Benoit Boland, Stefanie Thevelin, Paul A. F. Jansen, Denis O’Mahony, Nicolas Rodondi, Anne Spinewine

“…Consensus was reached on seven outcomes, which constitute the core outcome set: drug-related hospital admissions; drug overuse; drug underuse; potentially inappropriate medications; clinically significant drug-drug interactions; health-related quality of life; pain relief. …”
Get full text

Implementation of medication reconciliation in outpatient cancer care by Ernie Mak, Lucy Ma, Vishal Kukreti, Melanie Powis, Ryan Kirkby, Monika K Krzyzanowska, Celina Dara, Alyssa Macedo, Saidah Hack, Lyndon Morley, Hemangi Dave

“…Background Medication reconciliation (MedRec) is a process where providers work with patients to document and communicate comprehensive medication information by creating a complete medication list (best possible medication history (BPMH)) then reconciling it against what patient is actually taking to identify potential issues such as drug-drug interactions. We undertook an environmental scan of current MedRec practices in outpatient cancer care to inform a quality improvement project at our centre with the aim of 30% of patients having a BPMH or MedRec within 30 days of initiating treatment with systemic therapy.Methods We conducted semi-structured interviews with key stakeholders from 21 cancer centres across Canada, probing on current policies, and barriers and facilitators to MedRec. …”
Get full text

Analysis of the UDP-Glucosyltransferase (<i>UGT</i>) Gene Family and Its Functional Involvement in Drought and Salt Stress Tolerance in <i>Phoebe bournei</i> by Hengfeng Guan, Yanzi Zhang, Jingshu Li, Zhening Zhu, Jiarui Chang, Almas Bakari, Shipin Chen, Kehui Zheng, Shijiang Cao

“…<i>UGT</i> genes can exert their regulatory effects through mechanisms such as post-transcriptional modification, substrate subtype specificity, and drug interactions. <i>Phoebe bournei</i> is an economically significant tree species that is endemic to southern China. …”
Get full text

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study by Ayşe Serra Artan, Şafak Mirioğlu, Zulal İstemihan, Elif Aksoy, Ahmet Burak Dirim, Bilger Çavuş, Özgür Akın Oto, Aslı Çifçibaşı-Örmeci, Fatih Beşışık, Yaşar Çalışkan, Savaş Öztürk, Halil Yazıcı, Sabahattin Kaymakoğlu, Aydın Türkmen

“…However, cautious monitoring of trough levels of calcineurin inhibitorss is needed due to potential drug-drug interactions during the treatment episode.…”
Get full text

Polyporenic Acids from the Mushroom <i>Buglossoporus quercinus</i> Possess Chemosensitizing and Efflux Pump Inhibitory Activities on Colo 320 Adenocarcinoma Cells by Kristóf Felegyi, Zsófia Garádi, Bálint Rácz, Gábor Tóth, Viktor Papp, Imre Boldizsár, András Dancsó, Gabriella Spengler, Szabolcs Béni, Attila Ványolós

“…A P-glycoprotein efflux pump modulatory test on resistant Colo 320 cells highlighted that fungal metabolites <b>3</b>, <b>5</b>, <b>8</b>, and <b>10</b>–<b>12</b> have the ability to inhibit the efflux pump activity of cancer cells. Moreover, the drug interactions of triterpenes with doxorubicin were studied by the checkerboard method. …”
Get full text

Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted protein complexes by Wu, Min, Yu, Qi, Li, Xiaoli, Zheng, Jie, Huang, Jing-Fei, Kwoh, Chee Keong

“…For instance, proteins involved in multiple complexes (the overlapping proteins) are potential drug targets; the drug-complex network is utilized to investigate multi-target drugs and drug-drug interactions; and the disease-specific complex-drug networks will provide new clues for drug repositioning. …”
Get full text
Get full text

Apiaceae Essential Oils: Boosters of Terbinafine Activity against Dermatophytes and Potent Anti-Inflammatory Effectors by Adriana Trifan, Simon Vlad Luca, Andra-Cristina Bostănaru, Mihai Brebu, Alexandra Jităreanu, Romeo-Teodor Cristina, Krystyna Skalicka-Woźniak, Sebastian Granica, Monika E. Czerwińska, Aleksandra Kruk, Hélène Greige-Gerges, Elwira Sieniawska, Mihai Mareș

“…Although terbinafine represents the preferred treatment, its clinical use is hampered by side effects, drug–drug interactions, and the emergence of resistant clinical isolates. …”
Get full text

SLCO1B1 and CYP3A4 allelic variants associated with pharmacokinetic interactions and adverse reactions induced by simvastatin and atorvastatin used in Peru: Clinical implications by Angel T. Alvarado, Ana María Muñoz, Roberto O. Ybañez-Julca, Mario Pineda-Pérez, Nesquen Tasayco-Yataco, María R. Bendezú, Jorge A. García, Felipe Surco-Laos, Haydee Chávez, Doris Laos-Anchante, Aura Molina-Cabrera, Carmela Ferreyra-Paredes, Nelly Vega-Ramos, Patricia Castillo-Romero, Javier Chávez-Espinoza, Juan Panay-Centeno, Eliades Yarasca-Carlos

“…The keywords were: “statin”, “atorvastatin”, “simvastatin” in combination with “pharmacokinetics”, “pharmacogenetics”, “CYP3A4”, “SLCO1B1” or “drug interactions” considering the eligibility criteria defined by the PRISMA-2020 international statement. …”
Get full text

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation by Pável Olivera, César Velásquez-Escandón, Desirée Campoy, Katia Flores, Tania Canals, Erik Johansson, María José Herranz, Laia Martínez, Juan José Cerezo-Manchado, Ramón Salinas

“…Objective During the first wave of the SARS-CoV-2 pandemic, management of anticoagulation therapy in hospitalized patients with atrial fibrillation (AF) was simplified to low-molecular-weight heparin (LMWH) followed by oral anticoagulation, mainly owing to the risk of drug–drug interactions. However, not all oral anticoagulants carry the same risk. …”
Get full text

In Vitro and In Silico Biological Studies of 4-Phenyl-2-quinolone (4-PQ) Derivatives as Anticancer Agents by Yi-Fong Chen, Bashir Lawal, Li-Jiau Huang, Sheng-Chu Kuo, Maryam Rachmawati Sumitra, Ntlotlang Mokgautsi, Hung-Yun Lin, Hsu-Shan Huang

“…Pharmacokinetics (PKs) indicated that these 4-PQs displayed good drug-likeness and bioavailability, and had no cardiotoxic side effects or carcinogenicity, but we detected risks of drug–drug interactions and AMES toxicity (mutagenic). However, structural modifications of these 4-PQs could improve their PK properties and reduce their side effects, and their promising anticancer activities attracted our attention for further studies.…”
Get full text

<i>Abelmoschus esculentus</i> (L.) Moench Pod Extract Revealed Antagonistic Effect against the Synergistic Antidiabetic Activity of Metformin and Acarbose upon Concomitant Administ... by Md. Anamul Haque, Md. Sanower Hossain, Nur Muhammad Abu Sayed, Mohammad Touhidul Islam, Md. Robin Khan, Foyez Ahmmed, Fatama Tous Zohora, Duygu Ağagündüz, Long Chiau Ming, Raffaele Capasso

“…Further study is required to find the molecular insight of drug interactions in combination therapy of medicinal plants for diabetes.…”
Get full text

Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review by Agnese Maria Fioretti, Tiziana Leopizzi, Daniele La Forgia, Raffaele De Luca, Donato Oreste, Riccardo Inchingolo, Pietro Scicchitano, Stefano Oliva

“…However, in patients with thrombocytopenia, renal failure, or those receiving anticancer regimens with potential for drug-drug interactions, LMWH is still the mainstay of care. …”
Get full text

Prognosis in Patients Who were Diagnosed as Having Stroke, Using Warfarin, and Aged Over Eighty Years: A Clinical Observation by R. Gökçen Gözübatık Çelik, Hayriye Küçükoğlu, Eda Çoban, Songül Şenadım, Ayhan Köksal

“…Objective: Warfarin treatment is a partially preferred prophylactic treatment in patients with ischemic stroke with advanced age due to possible adverse events/ drug interactions. In this study, we aimed to investigate the frequency of warfarin use, possible adverse events, and reasons for discontinuation of treatment in patients with stroke aged over 80 years. …”
Get full text

Effects of Polyphenols on P-Glycoprotein (ABCB1) Activity by Kuljeet Singh, Szabolcs Tarapcsák, Zsuzsanna Gyöngy, Zsuzsanna Ritter, Gyula Batta, Rosevalentine Bosire, Judit Remenyik, Katalin Goda

“…Our results also call attention to the potential risks of drug–drug interactions (DDIs) associated with the consumption of dietary polyphenols concurrently with chemotherapy treatment involving Pgp substrate/inhibitor drugs.…”
Get full text

Micronutrient Status of Critically Ill Patients with COVID-19 Pneumonia by Sander Rozemeijer, Henrike M. Hamer, Annemieke C. Heijboer, Robert de Jonge, Connie R. Jimenez, Nicole P. Juffermans, Romein W. G. Dujardin, Armand R. J. Girbes, Angélique M. E. de Man

“…Micronutrient deficiencies can develop in critically ill patients, arising from factors such as decreased intake, increased losses, drug interactions, and hypermetabolism. These deficiencies may compromise important immune functions, with potential implications for patient outcomes. …”
Get full text

Adverse Drug Reactions during COVID-19 Treatment: A Comprehensive Analysis Focused on Hospitalized Patients, with the Use of a Survey in Cuba in 2020 by Lizette Gil-del-Valle, Rosario Gravier-Hernández, Waldemar Baldoquin-Rodríguez, Beatriz Sierra-Vázquez, Ana Beatriz Perez-Díaz, Pablo Sariol-Resik, Tatiana Prieto-Dominguez, Mario Manuel Delgado-Guerra, Joniel Arnoldo Sánchez- Márquez, Olga Elena López-Fernández, Faustina Fonseca-Betancourt, Liana Valdés-Lanza, Odalys Orraca-Castillo, Xaveer Van Ostade, Wim Vanden Berghe, Veerle Vanlerberghe, M. Guadalupe Guzmán-Tirado

“…Each potential ADR case was assessed for causality based on the WHO-UMC algorithm, concomitant drug influences, and the presence of any drug-drug interactions (DDI). Results. The total frequency of ADRs was 55%, with predominantly gastrointestinal disorders and general symptoms (23% vs 20%). 95.1% of ADRs occurred within 10 days after treatment and 42 potential DDI in 55.5% of patients (61/110) were observed. …”
Get full text